Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature

BACKGROUND: Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator. CASE PRESENTATIONS: We report a series of four patients, diagnosed w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Song, Johanna S., Tawa, Marianne, Chau, Nicole G., Kupper, Thomas S., LeBoeuf, Nicole R.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356405/
https://ncbi.nlm.nih.gov/pubmed/28302100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3194-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars